Medical » Growth Hormone Consensus Statement
On June 15, 2009, the PWS Association (USA) Clinical Advisory Board put out a consensus statement regarding growth hormone treatment in Prader-Willi Syndrome. It states:
Since the commerical release of recombinant human growth hormone (GH) in 1985, therapeutic use of this medication has been studied in a variety of medical conditions and genetic syndromes. Based on current medical knowledge, the Clinical Advisory Board of the Prader-Willi Syndrome Association (USA) has drafted and approved this policy statement to guide health care providers in the use of GH treatment in individuals with Prader-Willi Syndrome (PWS). Currently, 60% of the individuals in the PWSA (USA) database are receiving GH therapy. Current considerations regarding the use of GH treatment in PWS can be divided into the following categories:
1. GH treatment of infants/children with PWS to improve body composition abnormalities and improve body composition abnormalities and improve linear growth
2. GH treatment of adults with PWS to improve body composition abnormalities and improve bone mineral
Numerous studies indicate that GH deficiency occurs frequently in children with PWS and that treatment with GH is efficacious in improving the growth and body composition of these children.